<code id='8918EB4BED'></code><style id='8918EB4BED'></style>
    • <acronym id='8918EB4BED'></acronym>
      <center id='8918EB4BED'><center id='8918EB4BED'><tfoot id='8918EB4BED'></tfoot></center><abbr id='8918EB4BED'><dir id='8918EB4BED'><tfoot id='8918EB4BED'></tfoot><noframes id='8918EB4BED'>

    • <optgroup id='8918EB4BED'><strike id='8918EB4BED'><sup id='8918EB4BED'></sup></strike><code id='8918EB4BED'></code></optgroup>
        1. <b id='8918EB4BED'><label id='8918EB4BED'><select id='8918EB4BED'><dt id='8918EB4BED'><span id='8918EB4BED'></span></dt></select></label></b><u id='8918EB4BED'></u>
          <i id='8918EB4BED'><strike id='8918EB4BED'><tt id='8918EB4BED'><pre id='8918EB4BED'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:explore    Page View:8726
          Paul Berggreen, a gastroenterologist at Arizona Digestive Health who formed a new lobbying group for independent physician practices. Arizona Digestive Health/ GI Alliance

          Private equity gets a bad rap in health care. But some doctors see that kind of cash and consolidation as the only way for their practices to survive — and now, they’re taking that message to Washington.

          Lower pay, difficult negotiations with insurance companies, regulatory requirements from both government and commercial payers, expensive and inefficient IT systems, and the challenge of competing against hospital systems have created a “cascade of problems that seem like they are almost insurmountable” for independent practices, said Paul Berggreen, a gastroenterologist at Arizona Digestive Health.

          advertisement

          Berggreen is joining with other doctors to start a lobbying group for private practices, the brand-new American Independent Medical Practice Association, or AIMPA, to fight against those problems and advocate for private practice physicians.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Gene therapy’s promise and the high cost of hope
          Gene therapy’s promise and the high cost of hope

          AdobeAtthebustlingChicagoO’Hareairport,myluggageandIcollidedwithanelderlycouple.MyheartsankwhenIreal

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Readout LOUD podcast: The Sarepta saga, decoding biotech hype

          Whenisafailurenotafailure?DoestheFDAhavespecialrulesforSareptaTherapeutics?Andhowdoyousay“brash”inFr